We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-22.77%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.72B
AUM Growth
-$1.36B
Cap. Flow
-$888M
Cap. Flow %
-51.56%
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$37.8M
2
GH icon
Guardant Health
GH
+$19.9M
3
LUNG icon
Pulmonx
LUNG
+$15.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$11.2M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18M
2
CCCC icon
C4 Therapeutics
CCCC
+$15.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.5M
4
ICUI icon
ICU Medical
ICUI
+$12.8M
5
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.95%
2 Industrials 0.3%
3 Consumer Staples 0.27%
4 Materials 0.11%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DGX icon
226
PUT
Quest Diagnostics
DGX
$26.2B
– –
-184,200
Closed -$25.2M
ELVN icon
227
Enliven Therapeutics
ELVN
$4.24B
– –
-49,159
Closed -$370K
ESTA icon
228
CALL
Establishment Labs
ESTA
$2.25B
– –
-945,200
Closed -$63.7M
GILD icon
229
PUT
Gilead Sciences
GILD
$168B
– –
-100,000
Closed -$5.95M
CBIO
230
Crescent Biopharma
CBIO
$610M
– –
-877
Closed -$100K
ICUI icon
231
CALL
ICU Medical
ICUI
$4.48B
– –
-59,600
Closed -$13.3M
ICUI icon
232
ICU Medical
ICUI
$4.48B
– –
-57,700
Closed -$12.8M
IGMS
233
CALL
DELISTED
IGM Biosciences
IGMS
– –
-100,000
Closed -$2.67M
ILMN icon
234
CALL
Illumina
ILMN
$29.1B
– –
-66,820
Closed -$22.7M
IMUX icon
235
Immunic
IMUX
$217M
– –
-68,329
Closed -$4.38M
INSP icon
236
CALL
Inspire Medical Systems
INSP
$1.68B
– –
-35,000
Closed -$8.98M
IRON icon
237
Disc Medicine
IRON
$3.09B
– –
-16,537
Closed -$690K
IRTC icon
238
CALL
iRhythm Holdings
IRTC
$4.13B
– –
-85,000
Closed -$13.4M
ITGR icon
239
PUT
Integer Holdings
ITGR
$4.25B
– –
-37,500
Closed -$3.02M
JNJ icon
240
PUT
Johnson & Johnson
JNJ
$629B
– –
-150,000
Closed -$26.6M
LMAT icon
241
PUT
LeMaitre Vascular
LMAT
$1.88B
– –
-148,200
Closed -$6.89M
LQDA icon
242
Liquidia Corp
LQDA
$7.01B
– –
-251,604
Closed -$1.3M
LUNG icon
243
CALL
Pulmonx
LUNG
$98.4M
– –
-554,700
Closed -$13.8M
MAPS
244
DELISTED
WM TECHNOLOGY INC A
MAPS
– –
-178,000
Closed -$1.39M
MDT icon
245
CALL
Medtronic
MDT
$116B
– –
-400,000
Closed -$44.4M
MRNA icon
246
CALL
Moderna
MRNA
$25.4B
– –
-50,000
Closed -$8.61M
MRUS
247
DELISTED
Merus
MRUS
– –
-66,547
Closed -$1.76M
NAUT icon
248
Nautilus Biotechnolgy
NAUT
$114M
– –
-244,698
Closed -$1.06M
NNOX icon
249
PUT
Nano X Imaging
NNOX
$71M
– –
-200,000
Closed -$2.17M
NTLA icon
250
Intellia Therapeutics
NTLA
$1.69B
– –
-104,073
Closed -$5.28M
8 9
10
11 12

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.

  • Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
  • Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
  • Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
  • Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
  • Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
  • Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
  • Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.